A government panel of experts in India is investigating for any reported domestic cases of blood clotting, even mild ones, as a side effect of the COVID-19 vaccines being administered in India. India is currently administering AstraZeneca’s COVID-19 vaccine, which is manufactured by the Serum Institute and branded Covishield, and a shot developed by Bharat Biotech called COVAXIN, all in India. According to Reuters, the review comes after Europe’s drug regulator, the European Medicines Agency, EMA, found a possible link between AstraZeneca’s vaccine and rare blood clotting issues in adults who had received the shot, although it added the vaccine’s advantages still outweighed the risks.
The issue of blood clot is a cause of palpable fear among users of AstraZeneca vaccines, particularly in Nigeria. A source said the investigations were into the side-effects of blood clots that have been seen in people who received Covishield and Covaxin, and even mild cases are being looked into. Following Europe’s announcement, several countries have announced restrictions on the use of the AstraZeneca vaccine in younger people.
But the vaccine has been widely distributed across the world. On Thursday, the COVAX Facility announced that it had distributed up to 38 million doses to 100 countries.
It would be recalled that Nigeria received 3.92 million doses of the vaccine under the facility and has rolled out its vaccination campaign across the 36 states of the federation including the Federal Capital Territory, FCT.